Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Black Diamond Therapeutics ( (BDTX) ) has provided an update.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, has announced major changes as part of a corporate restructuring to focus on its lead program BDTX-1535 for non-small cell lung cancer. The plan includes cost-saving measures like reducing the workforce and general expenses, which are expected to extend the company’s cash runway into the second quarter of 2026. Concurrently, the company has seen the departure of key executives, including Fang Ni, the Chief Business Officer, Chief Financial Officer, and Principal Financial Officer, who is being replaced by Erika Jones. The restructuring aims to prioritize resources, advance the development of BDTX-1535, and seek partners for the deprioritized BDTX-4933 program.
Learn more about BDTX stock on TipRanks’ Stock Analysis page.
